Skystar Bio-Pharmaceutical Company  

(Public, NASDAQ:SKBI)   Watch this stock  
Find more results for SKBI
5.11
-0.05 (-0.97%)
Jul 31 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 5.10 - 5.15
52 week 1.43 - 8.22
Open 5.10
Vol / Avg. 2,618.00/37,138.00
Mkt cap 38.86M
P/E 3.63
Div/yield     -
EPS 1.41
Shares 7.60M
Beta 1.27
Inst. own 19%
May 16, 2014
Q1 2014 SKYSTAR BIO-PHARMACEUTICAL COMPANY Earnings Conference Call - Webcast
May 15, 2014
Q1 2014 SKYSTAR BIO-PHARMACEUTICAL COMPANY Earnings Release
More events from DailyFinance »    

Key stats and ratios

Q1 (Mar '14) 2013
Net profit margin 14.28% 24.79%
Operating margin 17.16% 30.63%
EBITD margin - 34.67%
Return on average assets 2.89% 8.36%
Return on average equity 3.54% 10.19%
Employees 317 -
CDP Score - -

Address

4/F, Building B, Chuangye Square No.48 Keji Road Gaoxin District
XI'AN, SXI 710065
China
+86-29-88193188 (Phone)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Skystar Bio-Pharmaceutical Company (Skystar) is a holding company. The Company is engaged in the research, development, production, marketing, and sales of veterinary healthcare and medical care products. It has four product lines: micro-organism products line, which include over 16 products; veterinary medicine line for poultry and livestock, which includes over 245 products; feed additives line, which includes over 16 products, and bio-pharmaceutical veterinary vaccine line, which includes over 10 products. All of the Company�s operations are carried out by Xi�an Tianxing Bio-Pharmaceutical Co., Limited (Xi�an Tianxing), a People�s Republic of China (PRC) joint stock company that the Company controls through contractual arrangements originally between Skystar Bio-Pharmaceutical (Cayman) Holdings Co., Ltd. (Skystar Cayman) and Xi�an Tianxing. As of December 31, 2011, it had over 3,846 customers in 29 provinces in China.

Officers and directors

Weibing Lu Chairman of the Board, Chief Executive Officer
Age: 50
Bio & Compensation  - Reuters
Bing Mei Chief Financial Officer
Age: 49
Bio & Compensation  - Reuters
Wei Wen Secretary, Director
Age: 45
Bio & Compensation  - Reuters
R. Scott Cramer Director
Age: 49
Bio & Compensation  - Reuters
Mark D. Chen Independent Director
Age: 45
Bio & Compensation  - Reuters
Qiang Fan Independent Director
Age: 57
Bio & Compensation  - Reuters
Chengtun Qu Independent Director
Age: 47
Bio & Compensation  - Reuters
Weirong Shen Independent Director
Age: 47
Bio & Compensation  - Reuters